Related Experiment Video
Updated: May 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria
Gillian M Keating1, Katherine A Lyseng-Williamson, Kate McKeage
1Adis, Auckland, New Zealand. demail@adis.co.nz
Abstract:
The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Nephrotic Syndrome III : Nursing Management
